Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Springworks Therapeutics Inc (SWTX)

Springworks Therapeutics Inc (SWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
SpringWorks Therapeutics: Q1 Earnings Snapshot

SpringWorks Therapeutics: Q1 Earnings Snapshot

SWTX : 42.31 (+2.12%)
5 Biotech Stocks With 26% Upside Potential or More

As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.

$SPX : 5,230.48 (+0.17%)
NVO : 132.52 (+0.08%)
BIIB : 222.75 (-1.15%)
KNSA : 19.64 (+0.31%)
SWTX : 42.31 (+2.12%)
RLAY : 6.52 (+1.56%)
ADPT : 4.12 (+8.42%)
GS : 460.50 (+1.53%)
SpringWorks Therapeutics: Q4 Earnings Snapshot

SpringWorks Therapeutics: Q4 Earnings Snapshot

SWTX : 42.31 (+2.12%)
SpringWorks Therapeutics: Q3 Earnings Snapshot

SpringWorks Therapeutics: Q3 Earnings Snapshot

SWTX : 42.31 (+2.12%)
SpringWorks Therapeutics: Q2 Earnings Snapshot

SpringWorks Therapeutics: Q2 Earnings Snapshot

SWTX : 42.31 (+2.12%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END

KTTA : 6.70 (-3.60%)
DAWN : 16.33 (+1.74%)
SWTX : 42.31 (+2.12%)
VSTM : 12.52 (+4.16%)
KNTE : 2.65 (-0.38%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

/PRNewswire/ -- Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue....

KTTA : 6.70 (-3.60%)
SWTX : 42.31 (+2.12%)
DAWN : 16.33 (+1.74%)
VSTM : 12.52 (+4.16%)
KNTE : 2.65 (-0.38%)
SpringWorks Therapeutics: Q1 Earnings Snapshot

SpringWorks Therapeutics: Q1 Earnings Snapshot

SWTX : 42.31 (+2.12%)
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s...

BGNE : 162.50 (+0.20%)
SWTX : 42.31 (+2.12%)
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023

MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1a/1b...

BGNE : 162.50 (+0.20%)
SWTX : 42.31 (+2.12%)

Barchart Exclusives

2 Copper Mining Stocks to Buy While They're Cheap
Discover two mining stocks that are poised to benefit from rising demand for copper, making them attractive investment opportunities in the current market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar